Vincristine Sulfate

Marginal Zone Lymphoma

Mayo ClinicSmall moleculePhase 2Active

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 59/ 100
Competitive Position: 95/ 100

Competitive context

99 Active assets in the Marginal Zone Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Etoposide University of Miami	Phase 2	BBB
Orelabrutinib Henan Cancer Hospital	Phase 4	BBB
Nivestim Fred Hutchinson Cancer Center	Phase 2	BBB
Cyclosporin A Fred Hutchinson Cancer Center	Phase 2	BBB
Irinotecan National Cancer Institute (NCI)	Phase 2	BB

View all 50 →

Same molecule, other indications

Vincristine Sulfate is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant

A

Indicative · Phase 3

81 / 100

diffuse large B-cell lymphomaActive

A

Indicative · Phase 2/3

80 / 100

childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.